Supplementary Figures 1-7. from SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer

Abstract

Supplementary Figure 1. SMARCA4 (212520_s_at) expression correlates with overall survival independent of stage in the Director's Challenge Study. Supplementary Figure 2. Low SMARCA4 (214360_at) expression correlates with decreased overall survival in the Director's Challenge Study. Supplementary Figure 3. Low SMARCA4 (208794_s_at) expression correlates with improved disease-specific survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Supplementary Figure 4. Low SMARCA4 (208794_s_at) expression correlates with improved overall survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Supplementary Figure 5. Low SMARCA4 (208793_x_at (A), 212520_s_at (B), 214360_at (C), and 215714_s_at (D)) expression correlates with improved disease-specific survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Supplementary Figure 6. SMARCA2 (206543_at) expression trends toward improved disease-specific survival with adjuvant cisplatin-based chemotherapy in the JBR.10 trial. Supplementary Figure 7. Mapping of the probe sets to the SMARCA4 gene.